Advertisement

Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial

      Abstract

      Background

      This phase II trial examined the activity and toxicity of second-line treatment with pazopanib after failure of first-line single-agent treatment with sunitinib or bevacizumab in patients with advanced clear cell renal carcinoma.

      Patients and Methods

      Fifty-five patients with metastatic clear cell renal carcinoma who had previously received first-line treatment with sunitinib (39 patients) or bevacizumab (16 patients) were enrolled. Patients received pazopanib 800 mg orally daily and were evaluated for response after 8 weeks of treatment. Responses were measured using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, and confirmed with repeated scans after 8 weeks. Patients with objective response or stable disease continued treatment until disease progression or unacceptable toxicity occurred.

      Results

      Fifteen of 55 patients (27%) had objective response to pazopanib. An additional 27 patients (49%) had stable disease, for a disease control rate of 76%. After a median follow-up of 16.7 months, the median progression-free survival for the entire group was 7.5 months (95% confidence interval, 5.4-9.4 months). Similar progression-free survival was observed regardless of whether previous treatment was with sunitinib or bevacizumab. The estimated overall survival rate for the entire group at 24 months was 43%.

      Conclusion

      Pazopanib is an active agent for the treatment of advanced clear cell renal carcinoma, even after failure of sunitinib or bevacizumab. Treatment with pazopanib should be considered early in the sequence of therapy for patients with advanced renal cell carcinoma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103-2111
        • Sternberg C.N.
        • Davis I.D.
        • Mardiak J.
        • et al.
        Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
        J Clin Oncol. 2010; 28: 1061-1068
        • Rini B.I.
        • Escudier P.
        • Tomczak A.
        • et al.
        Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of a phase III AXIS trial.
        J Clin Oncol. 2011; 29 (abstract 4503): 289
        • Escudier B.
        • Bellmunt J.
        • Négrier S.
        • et al.
        Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
        J Clin Oncol. 2010; 28: 2144-2150
        • Rini B.I.
        • Michaelson M.D.
        • Rosenberg J.E.
        • et al.
        Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
        J Clin Oncol. 2008; 26: 3743-3748
        • Rini B.I.
        • Wilding G.
        • Hudes G.
        • et al.
        Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 4462-4468
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Kaplan E.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53: 457-481
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • et al.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530-2540
        • Bukowski R.M.
        • Kabbinavar F.F.
        • Figlin R.A.
        • et al.
        Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
        J Clin Oncol. 2007; 25: 4536-4541
        • Hainsworth J.D.
        • Spigel D.R.
        • Burris H.A.
        • et al.
        Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
        J Clin Oncol. 2010; 28: 2131-2136
        • Waterhouse D.M.
        • Penley W.C.
        • Webb C.D.
        • et al.
        Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): a Sarah Cannon Research Institute phase I/II trial.
        J Clin Oncol. 2011; 29 (abstract 4629): 320
        • Feldman D.R.
        • Baum M.S.
        • Ginsberg M.S.
        • et al.
        Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 1432-1439
        • Kumar R.
        • Knick V.B.
        • Rudolph S.K.
        • et al.
        Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
        Mol Cancer Ther. 2007; 6: 2012-2021
        • Rini B.I.
        • Halabi S.
        • Rosenberg J.E.
        • et al.
        Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
        J Clin Oncol. 2008; 26: 5422-5428